What does ISO 10993-3 genotoxicity testing mean in practice?
ISO 10993‑3 assesses potential genotoxic risks of a medical device and forms a key component of the ISO 10993‑1 Biological Evaluation. The standard addresses irreversible biological effects, particularly DNA damage, and is relevant whenever a device contains or may release substances with genotoxic potential. It is especially important for invasive, long‑term or implantable devices.
The in‑vitro testing strategy covers different mechanisms of genotoxic damage. Typical assays include bacterial reverse mutation (Ames test), Mouse lymphoma test (MLA) and micronucleus tests in mammalian cells. The specific test battery is defined case by case, based on material type, exposure duration and regulatory expectations, ensuring a robust and protective evaluation.
Sample preparation follows ISO 10993‑12 to mirror clinically relevant exposure. Depending on the device, direct test specimens or extracts in appropriate media are used. Time–temperature profiles are selected to simulate a realistic worst‑case scenario without overloading the biological test system. All parameters are documented to support regulatory review.
Genotoxicity results are integrated with chemical data (ISO 10993‑18) and other biological endpoints within the ISO 10993‑1 Biological Evaluation. Negative findings support the conclusion of low genotoxic risk, while positive or borderline results require expert toxicological assessment, potential follow‑up studies and risk characterization.
Norm criteria – at a glance
| Norm criterion | Requirement / content | Note |
|---|---|---|
| Objective | Assess genotoxic risk | Hazard identification |
| Approach | In-vitro strategy | Risk-based |
| Sample preparation | ISO 10993-12 aligned | Contact & duration |
| Reporting | QES-signed | Traceable |
| Integration | Input for ISO 10993-1 | Assessed externally |
How we test your medical device – step by step
- Request a quote by phone or online. Key inputs: device, materials/components, contact type and exposure duration, and the device condition (e.g., sterilized/reprocessed).
- Send your device after accepting the quote. Please provide the sample in the marketed/used state where possible (including reprocessed state if applicable).
- Upon receipt, we start testing and document sample logistics and—where relevant—ISO 10993-12 aligned preparation/extraction parameters.
- We perform ISO 10993-3 in-vitro genotoxicity testing and document results to support downstream Biological Evaluation.
- You receive a digital, QES-signed report with professional interpretation. Upon request, we coordinate next steps through external toxicology (ISO 10993-17) and the ISO 10993-1 Biological Evaluation.
Why HygCen?
- DAkkS accredited testing laboratory (DIN EN ISO/IEC 17025) with GLP-compliant processes.
- Risk-based study design aligned with intended contact type, duration and use.
- Testing in the original state, including relevant processing/sterilization/reprocessing influences.
- Digital, QES-signed report with expert interpretation for MDR technical documentation.
- One-stop coordination: we manage interfaces to independent toxicologists for ISO 10993-17 and the ISO 10993-1 Biological Evaluation when needed.
ISO 10993‑3 is relevant for devices that may release potentially genotoxic substances or contain materials suspected of causing DNA damage. It is especially significant for invasive, long‑term or implantable products. The standard is also triggered when ISO 10993‑18 chemical characterization identifies structural alerts. Results feed into ISO 10993‑1 and toxicological risk assessment.
The test battery typically consists of Ames test, chromosomal aberration assays and micronucleus tests. These assays cover different mechanisms of genotoxicity. The exact combination is selected case by case based on device characteristics and regulatory requirements.
Sample preparation follows ISO 10993‑12 using extracts or direct specimens. Time–temperature profiles and extraction media are selected on a risk basis to reflect realistic worst‑case exposure. All sample logic and handling steps are documented in detail.
Genotoxicity data are combined with chemical and biological evidence within the ISO 10993‑1 Biological Evaluation. Negative findings support low risk, while positive or borderline outcomes require additional assessment and potential follow‑up testing.
Timelines depend on the selected assays, sample design and whether repeat or confirmation studies are needed. Cell culture, exposure, incubation and evaluation require multiple laboratory phases, followed by interpretation and reporting. Schedules are defined in the project plan.
Related links
ISO 10993-12 – Sample preparation & reference materials, ISO 10993-18 – Chemical characterization, ISO 10993-10 – Skin sensitization, ISO 10993-5 – Cytotoxicity, ISO 10993-23 – Irritation, ISO 10993-4 – Hemocompatibility, Pyrogenicity & endotoxin – incl. ISO 10993-11 coordination, ISO 10993-1 – Biological Evaluation